Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients

Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widesprea...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Adv Hematol
Egile Nagusiak: Ait-Tahar, Kamel, Anderson, Amanda P., Barnardo, Martin, Collins, Graham P., Hatton, Chris S. R., Banham, Alison H., Pulford, Karen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi 2017
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5674480/
https://ncbi.nlm.nih.gov/pubmed/29204156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6527306
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak